Published in N Engl J Med on December 21, 2000
British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax (2003) 5.83
The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol (2014) 4.30
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. J Thromb Thrombolysis (2014) 2.07
The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (2002) 1.96
Role of tissue factor in cancer. J Clin Oncol (2009) 1.91
The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med (2007) 1.70
Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med (2012) 1.60
Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer (2007) 1.60
Concomitant and antecedent deep venous thrombosis and cancer survival in male US veterans. Leuk Lymphoma (2011) 1.50
von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood (2015) 1.46
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood (2015) 1.43
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37
Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol (2009) 1.35
Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer (2006) 1.31
Venous thromboembolic disease and cancer. Postgrad Med J (2006) 1.23
Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer (2004) 1.22
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Venous thromboembolism and prognosis in cancer. Thromb Res (2010) 1.16
Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. Phys Biol (2011) 1.13
The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study. Br J Cancer (2004) 1.13
Epidemiology of cancer-related venous thromboembolism. Best Pract Res Clin Haematol (2009) 1.11
Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol (2007) 1.07
Occult lung infarction may induce false interpretation of 18F-FDG PET in primary staging of pulmonary malignancies. Eur J Nucl Med Mol Imaging (2005) 1.04
Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res (2008) 1.04
Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J Gastroenterol (2006) 1.04
Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med (2012) 1.03
Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood (2008) 1.03
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy). BMC Cancer (2008) 1.02
Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res (2008) 0.99
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations. Perm J (2015) 0.98
Cancer-associated thrombosis: clinical presentation and survival. Cancer Manag Res (2013) 0.98
FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer (2009) 0.98
Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol (2010) 0.98
Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res (2007) 0.98
Arterial and venous thrombosis in cancer patients. Cardiol Res Pract (2011) 0.97
Cancer-associated thrombosis: prevention and treatment. Curr Oncol (2008) 0.95
Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome--a comprehensive cancer center experience. Vasc Health Risk Manag (2011) 0.95
Activation of blood coagulation in cancer: implications for tumour progression. Biosci Rep (2013) 0.94
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. Blood (2014) 0.94
Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res (2014) 0.94
Venous thromboembolic disease. J Natl Compr Canc Netw (2011) 0.93
Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study. Haematologica (2013) 0.93
Clues to occult cancer in patients with ischemic stroke. PLoS One (2012) 0.93
Venous thromboembolism in malignant gliomas. J Thromb Haemost (2009) 0.92
Do circulating tumor cells play a role in coagulation and thrombosis? Front Oncol (2012) 0.92
A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res (2011) 0.91
A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. J Thromb Thrombolysis (2016) 0.91
Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer. Medicine (Baltimore) (2015) 0.90
Development of coagulation factor probes for the identification of procoagulant circulating tumor cells. Front Oncol (2012) 0.90
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer (2009) 0.90
Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. PLoS One (2013) 0.89
The prothrombotic activity of cancer cells in the circulation. Blood Rev (2015) 0.88
Thrombosis and cancer. Nat Rev Clin Oncol (2012) 0.88
Venous thromboembolism and cancer risk among elderly adults in the United States. Cancer Epidemiol Biomarkers Prev (2014) 0.86
Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev (2010) 0.86
High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost (2010) 0.86
Venous thrombosis and cancer: from mouse models to clinical trials. J Thromb Haemost (2015) 0.86
Thrombosis is associated with inferior survival in multiple myeloma. Haematologica (2012) 0.86
Venous thromboembolism in hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2015) 0.84
Screening for cancer in venous thromboembolic disease. BMJ (2001) 0.84
Biomolecular markers of cancer-associated thromboembolism. Crit Rev Oncol Hematol (2013) 0.84
Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol (2014) 0.83
Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica (2012) 0.83
The risk of a second cancer after hospitalisation for venous thromboembolism. Br J Cancer (2005) 0.83
Evidence-based guidance on venous thromboembolism in patients with solid tumours. Curr Oncol (2014) 0.83
Implementing thrombosis guidelines in cancer patients: a review. Rambam Maimonides Med J (2014) 0.83
Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma. Cell Death Dis (2014) 0.83
Circulating Prostaglandin Biosynthesis in Colorectal Cancer and Potential Clinical Significance. EBioMedicine (2015) 0.83
Brain neoplasms and coagulation-lessons from heterogeneity. Rambam Maimonides Med J (2014) 0.83
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. Front Cardiovasc Med (2015) 0.82
CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer (2013) 0.82
Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study. PLoS One (2015) 0.82
Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? Support Care Cancer (2008) 0.82
Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J Thromb Haemost (2015) 0.81
Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer (2006) 0.81
Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer. PLoS One (2014) 0.81
The association of active cancer with venous thromboembolism location: a population-based study. Mayo Clin Proc (2011) 0.81
Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer: a Danish population-based cohort study. BMJ Open (2014) 0.81
Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy. Br J Cancer (2009) 0.81
Cancer and coagulation. Am J Hematol (2012) 0.80
Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res (2014) 0.80
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Selected hemostatic parameters in patients with pancreatic tumors. Am J Transl Res (2014) 0.80
Cancer and thrombosis: an increasingly important association. Support Care Cancer (2008) 0.80
Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients. Support Care Cancer (2014) 0.80
Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol (2016) 0.79
Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques. J Exp Clin Cancer Res (2014) 0.79
Venous thromboembolism in the cancer population: pathology, risk, and prevention. J Adv Pract Oncol (2012) 0.79
A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy. Respir Med Case Rep (2015) 0.79
Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: the OASIS-CANCER Study. J Stroke (2016) 0.79
Prevention and treatment of venous thromboembolism in patients with cancer. Can Pharm J (Ott) (2012) 0.79
Physiological levels of blood coagulation factors IX and X control coagulation kinetics in an in vitro model of circulating tissue factor. Phys Biol (2013) 0.79
Thromboembolism in gastrointestinal cancers. Gastrointest Cancer Res (2008) 0.79
Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One (2014) 0.79
Incidence of and risk factors for venous thromboembolism during surgical treatment for esophageal cancer: a single-institution study. Surg Today (2015) 0.79
The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull (1999) 14.29
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
Association between hospital and surgeon procedure volume and outcomes of total hip replacement in the United States medicare population. J Bone Joint Surg Am (2001) 7.67
The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health (1992) 6.97
Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (2001) 6.23
A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med (1994) 5.98
The framing effect of relative and absolute risk. J Gen Intern Med (1993) 4.87
The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med (1998) 4.41
Ethics of a prostate cancer screening trial. Lancet (1994) 4.21
Induced abortion and the risk of breast cancer. N Engl J Med (1997) 4.04
Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst (1997) 3.57
A pooled analysis of magnetic fields and childhood leukaemia. Br J Cancer (2000) 3.49
Risk for subsequent cancer after diagnosis of basal-cell carcinoma. A population-based, epidemiologic study. Ann Intern Med (1996) 3.18
Heterogeneity of hip fracture: age, race, sex, and geographic patterns of femoral neck and trochanteric fractures among the US elderly. Am J Epidemiol (1996) 3.16
Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum (1997) 2.93
Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol (2001) 2.48
Rheumatoid arthritis and cancer risk. Eur J Cancer (1996) 2.44
Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer (2003) 2.43
Appendectomy and subsequent risk of inflammatory bowel diseases. Surgery (2001) 2.35
Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer (1994) 2.33
Social and economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N Engl J Med (1988) 2.33
Hip fracture incidence and mortality in New England. Epidemiology (1991) 2.32
Smoking and estrogen-related disease. Am J Epidemiol (1984) 2.31
Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect (1998) 2.22
Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology (1998) 2.19
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol (2000) 2.18
The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol Ther (2015) 2.16
Jewish religion and risk of breast cancer. Lancet (1996) 2.14
A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group. N Engl J Med (1990) 2.13
Malignant tumours and psoriasis: climatotherapy at the Dead Sea. Br J Dermatol (1999) 2.06
Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer (1999) 1.98
Electric blanket or mattress cover use and breast cancer incidence in women 50-79 years of age. Epidemiology (2001) 1.96
The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med (1994) 1.96
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost (2009) 1.95
Overcoming potential pitfalls in the use of Medicare data for epidemiologic research. Am J Public Health (1990) 1.88
A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer (2003) 1.88
Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med (1998) 1.87
Autoimmune disease and risk for Parkinson disease: a population-based case-control study. Neurology (2009) 1.86
Non-neoplastic mortality of European workers who produce man made vitreous fibres. Occup Environ Med (1999) 1.83
Treatment and survival among elderly Americans with hip fractures: a population-based study. Am J Public Health (1994) 1.83
Effect of intravenous streptokinase on early mortality in patients with suspected acute myocardial infarction. A meta-analysis by anatomic location of infarction . Ann Intern Med (1990) 1.82
Air pollution from traffic at the residence of children with cancer. Am J Epidemiol (2001) 1.79
Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol (2002) 1.74
Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ (2000) 1.73
Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst (1999) 1.73
Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer (2005) 1.72
Benign anal lesions and the risk of anal cancer. N Engl J Med (1994) 1.67
Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control (2000) 1.61
Do parents of children with congenital malformations have a higher cancer risk? A nationwide study in Denmark. Br J Cancer (2002) 1.59
Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation. Aliment Pharmacol Ther (2011) 1.58
Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control (2000) 1.56
Incidence of childhood cancer in Denmark 1943-1984. Int J Epidemiol (1989) 1.54
Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet (1999) 1.53
Occupational exposure to 60-hertz magnetic fields and risk of breast cancer in women. Epidemiology (1996) 1.51
Cancer following breast reduction surgery in Denmark. Cancer Causes Control (1997) 1.50
Fracture risk in the U.S. Medicare population. J Clin Epidemiol (1999) 1.49
Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum (1997) 1.49
Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ (1998) 1.48
Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control (1995) 1.47
Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer (1999) 1.44
Cancer staging may have different meanings in academic and community hospitals. J Clin Epidemiol (1991) 1.43
A genetic study of ulcerative colitis. Scand J Gastroenterol (1966) 1.42
Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial. Gut (1988) 1.42
Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control (1999) 1.42
KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer (2013) 1.41
Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group. Gastroenterology (1998) 1.40
Malignant melanoma among lithographers. Scand J Work Environ Health (1996) 1.40
Left-handedness in relation to breast cancer risk in postmenopausal women. Epidemiology (2000) 1.40
Birth characteristics, sibling patterns, and acute leukemia risk in childhood: a population-based cohort study. J Natl Cancer Inst (1997) 1.39
[Pernicious anemia and risk of cancer in Denmark]. Ugeskr Laeger (1997) 1.39
Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol (1998) 1.39
Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer (2001) 1.37
Cancer risk and mortality in users of calcium channel blockers. A cohort study. Cancer (2000) 1.36
A randomized controlled trial of low carbohydrate and low fat/high fiber diets for weight loss. Am J Public Health (1986) 1.33
Cigarette smoking and Parkinson's disease. Neurology (1986) 1.33
Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population-based study. Int J Cancer (1996) 1.33
Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol (1998) 1.33
Significantly lower incidence of cancer among patients with Huntington disease: An apoptotic effect of an expanded polyglutamine tract? Cancer (1999) 1.31
Genital talc exposure and risk of ovarian cancer. Int J Cancer (1999) 1.31
Spatial temporal patterns in childhood leukaemia: further evidence for an infectious origin. EUROCLUS project. Br J Cancer (1998) 1.31
Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer (1999) 1.29
Cancer in patients with ulcerative colitis. Int J Cancer (1995) 1.28
An air pollution model for use in epidemiological studies: evaluation with measured levels of nitrogen dioxide and benzene. J Expo Anal Environ Epidemiol (2000) 1.27
Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst (1993) 1.26
Connective tissue disease and other rheumatic conditions following breast implants in Denmark. Ann Plast Surg (1997) 1.24